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Abstract
Single-arm clinical trials are useful to evaluate antiretroviral regimens in certain populations of HIV-infected
treatment-naive patients for whom a randomized controlled trial is not feasible or desirable. They can also be
useful to establish initial estimates of efficacy and safety/tolerability of novel regimens to inform the design of
large phase III trials. In this article, we discuss key design considerations for such single-arm studies.
Introduction
The randomized controlled trial (RCT) is the goldstandard for evaluating clinical interventions, including
antiretroviral (ARV) therapy in treatment-naive HIV-infected
patients. There are, however, situations in which single-arm
clinical trials may be valuable. One such example concerns the
evaluation of a treatment in populations that may be excluded
from large phase III RCTs yet are not common enough to
populate a well-powered RCT specifically targeting that
population. This scenario is illustrated by HIV-infected pa-
tients with transmitted resistance to one or more ARVs who
are commonly excluded from phase III RCTs in ARV treat-
ment-naive patients. Some patients may also be inappropriate
for inclusion in an RCT due to preexisting conditions that may
compromise safety such as chronic renal failure, or skew
outcomes such as substance abuse. For many of these popu-
lations, the enrollment of the large number of patients nec-
essary for a separate RCT that includes regimens the patients
are able to take may not be viable, making a single-arm trial a
potential alternative.
Single-arm trials are also useful in assessing the efficacy
and safety/tolerability of novel regimens comprising one or
more already approved ARVs, as an initial assessment before
proceeding to larger scale evaluation in an RCT. When the
standard of care is already well defined from previous RCTs,
the established efficacy allows rational estimation of accept-
able efficacy/safety of the experimental intervention. In this
article, we discuss issues that are central to the design of
single-arm clinical trials in treatment-naive HIV-infected pa-
tients and illustrate them with the design of the AIDS Clinical
Trials Group (ACTG) study A5262.
Design Issues
The primary objective of a single-arm study of an ARV
regimen must be achievable without a concurrent comparator
arm, and parameters guiding interpretation of study findings
including threshold for success or failure must be prespecified
and well understood. Figure 1 illustrates prespecified guide-
lines for interpreting a hypothetical study. The primary ob-
jective of the study is to estimate regimen efficacy in a target
population as measured by the proportion of patients failing
to achieve and maintain virologic suppression below a de-
fined assay threshold. Given the lack of a concurrent com-
parator arm, the observed failure rate and the associated
two-sided confidence interval (CI) are compared with a pre-
specified maximally acceptable failure rate (threshold; we
discuss the choice of this threshold below). If the CI for the
failure rate is entirely below the threshold (scenario A in Fig.
1), then the regimen under evaluation is considered accept-
able and so may be recommended for use in the target pop-
ulation or, in a drug development program, for further
evaluation in a larger comparative RCT. Conversely, if the CI
is entirely above the threshold (scenario B), then regimen is
considered unacceptable and so not recommended for use or
further evaluation. If the CI includes the threshold of interest
(scenario C), the study may be considered inconclusive, and
1Statistical Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts.
2Division of Infectious Diseases, Northwestern University, Chicago, Illinois.
3Division of Infectious Diseases, Ohio State University, Columbus, Ohio.
4Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 29, Number 4, 2013
ª Mary Ann Liebert, Inc.
DOI: 10.1089/aid.2012.0180
652
consideration for use may depend on factors such as tol-
erability or availability of treatment options in the target
population.
In some situations, the definition of acceptable outcome may
need to be more stringent with scenario C also considered
unacceptable. In this case, only the upper bound of the CI is
relevant to the decision-making process and so a one-sided CI
might be used. However, there is a general consensus, in-
cluding from regulatory agencies,1–3 favoring the use of two-
sided CIs. Two-sided CIs also facilitate interim monitoring: if
the observed failure rate in the study is higher than might be
considered acceptable, then the lower bound of the CI gives a
sense of plausible true failure rates, information critical to de-
cisions that may be made by study monitoring committees,
such as whether to terminate a study early. In general, a
standard two-sided 95% CI is recommended though a 90% CI
might be appropriate particularly if further study of the regi-
men in the population of interest is expected (e.g., if the study is
to be followed by a larger RCT). To maintain the level of evi-
dence required before considering a regimen acceptable, when
a one-sided CI is used then the confidence bound should be the
same as the upper bound of the two-sided interval. For ex-
ample, if 95% would have been chosen for a two-sided CI, then
97.5% should be used for the one-sided confidence bound.
Example of a Single-Arm Clinical Trial
ACTG study A5262 was a prospective, multicenter, 52-
week single-arm study designed to evaluate the safety and
efficacy of raltegravir (RAL) plus ritonavir-boosted darunavir
(DRV/r) as initial combination ARV therapy in HIV-1-
infected ARV-naive participants with or without transmitted
nonnucleoside reverse transcriptase inhibitor (NNRTI) or
nucleos(t)ide reverse transcriptase inhibitor (NRTI) drug-
resistance mutations.4 Participants with plasma HIV-1 RNA
levels ‡ 5,000 copies/ml obtained within 90 days prior to
study entry were eligible. Participants were ineligible if the
screening HIV RT/protease genotype or any previous RT/
protease genotype showed more than one DRV resistance-
associated mutation (RAM) or L76V alone5 or if the partic-
ipants had one or more known major integrase inhibitor
resistance-associated mutations.6 There was no CD4 + cell
count restriction and patients with renal insufficiency not
requiring dialysis were allowed.
Plasma HIV-1 RNA was evaluated at study entry, and
at weeks 1, 4, 12, 24, 36, and 48 after starting the study drug;
HIV-1 RNA was also evaluated at week 52 if virologic failure
was suspected at week 48. The primary objective was to esti-
mate the cumulative proportion of ARV-naive participants ex-
periencing virologic failure at or before week 24 after initiating
RAL plus DRV/r. Virologic failure was defined as follows:
Week 12:
 Confirmed plasma HIV-1 RNA ‡ 1,000 copies/ml or
 Confirmed rebound from the week 4 value by 0.5 log10
copies/ml (for participants with week 4 value £ 50
copies/ml, confirmed rebound to > 50 copies/ml).
Week 24:
 Confirmed value > 50 copies/ml.
The study aimed to enroll 111 participants. Primary anal-
ysis used an intent-to-treat (ITT) approach, wherein any vi-
rologic failure was included in the analysis regardless of
whether the participant was on or off study treatment at the
time of measurement, but follow-up was censored if a par-
ticipant was lost to follow-up without previously meeting the
definition of virologic failure. The intent of the study was to
follow all participants for 52 weeks even if they discontinued
the study regimen.
The cumulative proportion of participants experiencing
virologic failure at or prior to week 24 was estimated using the
method of Kaplan and Meier with the associated two-sided
95% CI.7 It was prespecified that the regimen would be con-
sidered acceptable for further investigation if the 95% CI
around the proportion of participants experiencing virologic
failure was below 35%, and unacceptable if the 95% CI was
above or included 35%.
Choice of Outcome Measure
The interpretation of results from a single-arm trial is fa-
cilitated by use of a primary outcome measure that is identical
in definition, or nearly so, to that used in the trials to which the
current trial’s results will be compared. For example, for
A5262 a purely virologic endpoint was chosen to match
comparator ACTG studies A5095 and A5142, from which
week 24 failure rate estimates were available.
The duration of time over which the primary outcome
measure is evaluated also needs to be defined. For studies in
ARV-naive participants, the majority of virologic failures and
treatment discontinuations tend to occur early, often within
24 weeks of ARV initiation. Illustratively, among 765 partic-
ipants randomized to receive one of the two efavirenz-
containing regimens in ACTG A5095, 115 (15%) exhibited
virologic failure by week 48.8 Of these 115 failures, 76% failed
by week 24. Thus, the week 24 measure is likely to be ade-
quate for an initial assessment of the study regimen, whereas
2 to 3 years of follow-up would be needed to evaluate long-
term virologic outcome (determined largely by virologic re-
bound following suppression) as distinct from early outcome
(determined by lack of adequate initial suppression as well as
early rebound and treatment limiting toxicity).
As well as providing an earlier assessment of a regimen, a
relatively early endpoint can also provide pilot efficacy and
FIG. 1. Representative hypothetical confidence intervals
achieved at the end of the single-arm study and how each is
interpreted.
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safety data to larger RCTs evaluating the same regimen. For
example, while A5262 was ongoing, the European AIDS
Treatment Network designed a large phase III RCT (NEAT
001, NCT01066962) comparing RAL + DRV/r to DRV/r +
tenofovir/emtricitabine (TDF/FTC) in 800 treatment-naive
HIV-1-infected patients followed for 96 weeks. The A5262
study team was able to share primary (week 24) results with
the NEAT 001 team before A5262 follow-up of 52 weeks was
completed, alerting the NEAT 001 team of the potentially
lower than expected efficacy of the RAL + DRV/r arm in a
particular patient subgroup. Of note, a later endpoint may be
desirable if the single-arm study is likely to be the only trial of
the regimen in the target population, thus necessitating a
more comprehensive assessment.
Selection of Threshold for Unacceptable
Virologic Failure Rate
It is important to prespecify a threshold failure rate below
which the chosen primary outcome measure would be consid-
ered acceptable. Ideally, the threshold would be based on results
from recent trials, recognizing, however, that the populations
enrolled in these trials might be different from the target pop-
ulation of the trial being planned. A5262 study investigators
obtained the following week 24 failure rates for the efavirenz
and two NRTI arms of A5095 and A5142 from the study teams:
21% (95% CI 17% to 25%8) and 22% (17% to 28%9), respectively.
Dose-specific estimates ranging from 5% to 15% (with upper
bounds of the 95% CIs ranging from 17% to 30%) were available
for the raltegravir-based regimens of Merck 004.10
The design of RCTs comparing ARV regimens in treatment-
naive populations provides guidance for selecting acceptable
outcome thresholds for single-arm studies. In RCTs, a non-
inferiority bound of 10% is often used for the difference in
failure rates between arms. Thus, a reasonable approach in a
single-arm study in treatment-naive participants might be to
use a failure threshold that is 10% higher than the typical
failure rate observed in the superior (or noninferior) arms of
the larger recent randomized studies. In the Merck and the
two ACTG trials above, observed failures rates of 22% or
lower, and CI upper bounds of 30% or lower, suggest that true
failures rates might reasonably be less than 30%. Hence the
A5262 team considered that a true failure rate higher than 35%
would be unacceptable.
An important limitation of a single-arm study concerns the
choice of threshold rate when that threshold is based on re-
sults from studies of regimens that would no longer to be
considered acceptable or in populations that are quite differ-
ent. For example, for some regimens, higher pre-treatment
viral load may be associated with higher probability of viro-
logic failure. Thus if the population to be enrolled in the
single-arm study is likely to have a much lower distribution of
viral loads than populations in the earlier trials, then ob-
serving a failure rate lower than the threshold might be more
readily achieved than if a population with comparable viral
loads could be enrolled.
Power and Sample Size Considerations
The power, or true acceptance probability, of a single-arm
study with a sample size of N participants can be expressed as
the probability of concluding, at the completion of the study,
that the regimen is acceptable (i.e., the upper bound of the CI
around the proportion of participants experiencing virologic
failure is below the prespecified threshold), when the new
regimen is truly acceptable (i.e., the true failure rate takes
some value that is less than the threshold). This probability






n x I(pu < p0)
where 1 – a is the desired two-sided confidence level (e.g.,
95%), p0 is the failure rate threshold, p1 is the true (unob-
servable) failure rate for the study regimen, pU is the upper
bound of a 100(1 – a)% CI for failures among the sample size of
participants, and I ( ) is the indicator function (takes value 1 if
the enclosed statement is true and 0 otherwise).
For a given power and confidence interval coverage (e.g.,
95%), the corresponding necessary sample size, N, is found










Figure 2 illustrates the relationship between power
(y-axis), using a 95% CI, and the true (unobservable) viro-
logic failure rate (x-axis) when the threshold of interest is
35% for sample sizes, N, of 50, 100, and 150. For a given true
failure rate, as the sample size is increased, the power of a
study increases. For example, for a true failure rate of 20%,
the power increases from 57% for a sample size of 50 to 91%
and 98% for samples sizes of 100 and 150, respectively. In
A5262, a sample size of 100 was selected; anticipating a 10%
loss to follow-up, the accrual target was then increased to
111 participants.
Table 1 illustrates how the power of a study with a sample
size of 100 patients (prior to any adjustment for loss to follow-
up) varies according to the underlying true failure rate and the
threshold being used. For a given true failure rate, a lower
failure rate threshold gives lower power (and so the sample
size might be increased from 100 to achieve good power).
Conversely, for a given threshold, the power is also lower as
the true underlying failure rate increases.
FIG. 2. Operating characteristics of two-sided 95% confi-
dence interval for a failure rate threshold of 35% for sample
sizes of 50, 100, and 150 participants.
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Study Monitoring
Single-arm studies are usually small and—using an early
outcome measure (e.g., week 24 virologic failure rate)—
responses are observable in a relatively short period of time.
This characteristic facilitates monitoring of the data as they
accumulate. Ideally, there should be an early interim moni-
toring. A stopping guideline sets out the circumstances under
which the study could be terminated prior to study comple-
tion by all participants; this is usually when there is strong
evidence of unacceptable efficacy. On the other hand, if evi-
dence suggests a satisfactory regimen, it is beneficial to con-
tinue the study to obtain more precise efficacy and safety
information. Thus the primary purpose of interim monitoring
is to evaluate virologic failure rates and safety data early en-
ough in the study to prevent exposing current or additional
participants to a regimen associated with unacceptably poor
efficacy. Interim monitoring is usually performed by an entity
independent of the study team. In addition to efficacy moni-
toring, management of individual participants for toxicities
and treatment nonresponse is important, and is most often
done by the study team and clinical site investigators.
The schedule of interim monitoring and the stopping
guideline should be prespecified in the protocol after con-
sidering several factors including the primary endpoint week,
estimated accrual rate, and duration of the trial. To minimize
the risk of obtaining misleading findings from the interim
review, the review should be scheduled for a time when
the number of participants who have reached the primary
endpoint will be sufficient to estimate the virologic failure
rate with reasonable precision.
A5262 was monitored by an ACTG-appointed study
monitoring committee (SMC) that was independent of the
study team and clinicians enrolling patients into the study.
The initial interim review by the SMC was to occur at the
earlier of (1) 24 weeks after enrollment of the 40th participant
(when it was expected that the primary endpoint would be
available for about one-third of participants), or (2) 1 year
after the enrollment of the first participant, which meets re-
quirements of the National Institutes of Health for at least
annual monitoring. The stopping guideline specified that the
SMC might recommend closing or modifying the study if 19
or more of the first 40 participants to reach week 24 exhibited
virologic failure. After the initial interim review, the study
was to be monitored annually by the SMC. The A5262 stop-
ping guideline was defined using operating characteristics
such as those in Table 2.
A desirable operating characteristic of any stopping
guideline is that it leads to early study termination with high
probability when the underlying true failure rate is unac-
ceptably high, but with low probability when the true failure
rate might be considered acceptable. At an interim analysis,
one approach for defining a stopping guideline is to consider
stopping if a CI around the observed failure rate is entirely
above the threshold failure rate (as in scenario B in Fig. 1).
Given the sample size at the interim analysis (e.g., 40 in
A5262), the number of failures that need to be observed in
order for this to occur can then be calculated. For A5262, with
21 failures among 40 subjects, the observed proportion failing
is 53% and the associated CI is 37% to 68%, so just excluding
35%. Table 2 shows the probability of meeting this criterion
for various underlying true probabilities of failure.
The study team was concerned that the probability of
meeting this criterion might not be sufficiently high when the
true probability of failure was quite unacceptable (e.g., 68%
probability of meeting this criterion when the true failure rate
was 55%). They therefore considered using a slightly lower
Table 1. Power (Probability That 95% Confidence
Interval Will Exclude Threshold Failure Rates)
for Given True Failure Rates and a Fixed
Sample Size of 100 Evaluable Subjects
True virologic failure rate
Threshold
(rate to exclude by 95% CI) 15% 20% 25%
40.0% >99% 99% 90%
37.5% >99% 97% 72%
35.0% >99% 91% 55%
32.5% 99% 81% 37%
30.0% 93% 56% 14%
CI, confidence interval.
Table 2. Several Choices of Stopping Guideline (Threshold and Number of Participants Examined at Interim
Evaluation), and the Probability of Stopping Under Various True Failure Probabilities








95% CI excludes threshold
(Observed
proportion) 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60
36 0.30 17 (0.47) <1% 2% 9% 24% 46% 69% 87% 96%
36 0.35 19 (0.53) <1% <1% 2% 8% 22% 43% 67% 85%
38 0.30 18 (0.47) <1% 2% 8% 22% 45% 69% 87% 96%
38 0.35 20 (0.53) <1% <1% 2% 8% 22% 44% 68% 86%
40 0.30 19 (0.48) <1% 1% 7% 21% 43% 68% 87% 96%
40 0.35 21 (0.53) <1% <1% 2% 7% 21% 44% 68% 87%
42 0.30 20 (0.48) <1% 1% 6% 20% 42% 68% 87% 96%
42 0.35 22 (0.52) <1% <1% 2% 7% 21% 44% 69% 88%
44 0.30 20 (0.45) <1% 2% 10% 28% 53% 77% 92% 98%
44 0.35 23 (0.52) <1% <1% 1% 7% 21% 44% 70% 88%
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threshold for interim monitoring, specifically 30%. For this
interim monitoring threshold, observing 19 failures among 40
subjects gave a higher probability of meeting the criterion
when the true probability of failure was quite unacceptable
(e.g., 87% probability when the true failure rate was 55%).
Thus, in the event the regimen performs very poorly and 19
participants are seen to fail before the 40th participant reaches
week 24, the team will notify the SMC for an earlier review.
Table 2 shows related results for defining a stopping guideline
for sample sizes close to 40, to allow some flexibility in prac-
tice in the timing of the interim analysis (e.g., if slightly fewer
or more patients have the necessary data at the time that a
monitoring committee meeting occurs). This approach can be
extended to multiple interim reviews. Note that the CI is being
used here as a tool for choosing an acceptable stopping
guideline in the situation in which the regimen is unlikely to
be useful in practice and so adjustment of the CI for repeated
analyses is not a major concern.
In theory, however, if a trial involves interim analyses, the
calculation of multiple CIs (at each interim analysis and at the
final analysis), each with a coverage probability 100$[1 – a]%,
requires adjustment for these repeated analyses. In a study
that continues to its full sample size, interpretation of the 95%
CI is minimally impacted by the stopping rule and in general
practice the usual calculation of the (nominal) 95% CI is rea-
sonable. For example, for A5262 the probabilities of stopping
early under true failure rates of 15%, 20%, and 25% are all less
than 0.2%, not enough to change the probabilities in Table 1
appreciably. We do not advocate stopping a single-arm study
early for efficacy. However, if the investigator chooses to do
so, methods for calculating repeated CIs that allow for early
stopping might be considered.11
Conclusions
We have described design considerations for single-arm
studies in HIV-infected treatment-naive patients. A single-
arm design may also be appropriate in studies of treatment-
experienced patients who are difficult to recruit or for whom
restricted viable treatment options limit the availability of a
control regimen. This is illustrated by the ongoing study
evaluating maraviroc plus raltegravir plus darunavir/
ritonavir in exclusively CCR5-tropic, integrase-naive and dar-
unavir-naive HIV-1-infected patients with a history of triple-
class ARV treatment failure (NCT01013987). Furthermore,
single-arm trials can provide supportive data for drug devel-
opment.12 An example is the single-arm study requested by the
FDA to provide data on additional treatment-experienced
subjects at the recommended dose of darunavir/r to refine
estimated rates of failure and adverse events.13 Lastly, we note
that in a guidance about developing directing agents for the
treatment of hepatitis C virus (HCV), the FDA acknowledges
the value, in certain situations, of single-arm prospective trials
with historical controls in evaluating drugs for the treatment of
HCV infection in HIV/HCV coinfected subjects.14
Single-arm phase II studies have been commonly used in
oncology to assess the antitumor activity of new drugs. The
primary goal of oncology phase II trials is not to provide de-
finitive evidence of drug efficacy, but to propose a promising
drug for further investigations. Two-stage and multistage
designs intended to control for the average number of patients
required to make a correct decision have been well studied in
the literature.15–17 These designs require pauses to accrual
between stages.
Key potential shortcomings of single-arm studies include
limited generalizability to populations not included in the
study or comparability to other studies since observed failure
rates can be due to factors other than the investigational
regimen. For example, a very high virologic failure rate in a
single-arm study may be attributable to enrollment of a
poorly adherent population and not the antiviral efficacy of
the investigational regimen. Also, regimens in the RCTs
considered in designing a single-arm study, hence the as-
sumptions in designing the single-arm study, may be obsolete
by study completion, although this is less likely to occur for
small, short-duration single-arm studies.
Despite these limitations, single-arm studies have a unique
role in clinical trials when an RCT is not feasible or desirable,
and can provide critical pilot efficacy and safety data on novel
antiretroviral regimens.
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